Pharmacotherapeutics of prostaglandin E2 and 15 (S) 15-methyl prostaglandin F2 alpha in chronic schistosomal bladder ulcer: a clinico-endoscopic study.
The pharmacotherapeutic effects of prostaglandin E2 (PGE2) and 15 (S) 15-methyl PGF2 alpha given by different routes of administration, were studied in 20 normal persons and 100 patients with chronic schistosomal bladder ulcer in comparison to normal saline and antimony dimercaptosuccinate drug. Prostaglandins produced a rapid significant amelioration in the ulcer symptom complex with a good percentage of ulcer disappearance on cystoscopy, while the antimony dimercaptosuccinate treated group showed a less early response which improved with follow up. This was in contrast to prostaglandins which showed relapse in the symptom-complex in some cases after a follow up period of 2 months. The combined use of schistosomicidal drugs together with, or followed by, prostaglandins might give better results.
D000284:Administration, Oral; D002260:Carboprost / Q000008:administration & dosage / Q000627:therapeutic use*; D015232:Dinoprostone; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D011458:Prostaglandins E / Q000008:administration & dosage / Q000627:therapeutic use*; D011461:Prostaglandins F, Synthetic / Q000627:therapeutic use*; D012552:Schistosomiasis / Q000150:complications*; D014456:Ulcer / Q000188:drug therapy; D001745:Urinary Bladder Diseases / Q000188:drug therapy* / Q000209:etiology
D011458:Prostaglandins E; D011461:Prostaglandins F, Synthetic; D002260:Carboprost; D015232:Dinoprostone